Childhood acute lymphoblastic leukaemia--current status and future perspectives (Q34570023)

3 August 2017

1 reference

title

Childhood acute lymphoblastic leukaemia--current status and future perspectives (English)

1 reference

3 August 2017

1 reference

C H Pui

1 reference

3 August 2017

D Campana

series ordinal

1 reference

3 August 2017

W E Evans

series ordinal

1 reference

3 August 2017

publication date

1 October 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

597-607

1 reference

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Prenatal origin of acute lymphoblastic leukaemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Molecular genetics, natural history and the demise of childhood leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Topoisomerase II inhibitor-related acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Sex differences in prognosis for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

New definition of remission in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Visual and Verbal Short-Term Memory Deficits in Childhood Leukemia Survivors After Intrathecal Chemotheraphy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900516-2

7 January 2021

10.1016/S1470-2045(01)00516-2

Identifiers

DOI

1 reference

3 August 2017

1 reference